Provectus Biopharma (NYSE:PVCT) saw a large decline in short interest during the month of September. As of September 30th, there was short interest totalling 1,821,793 shares, a decline of 26.7% from the September 15th total of 2,487,008 shares. Approximately 0.9% of the company’s shares are sold short. Based on an average trading volume of 4,033,468 shares, the short-interest ratio is currently 0.5 days.
Provectus Biopharma Company Profile
Provectus Biopharmaceuticals, Inc is a development-stage biopharmaceutical company. The Company is engaged in developing pharmaceuticals for oncology and dermatology indications. The Company is focused on developing its prescription drug candidates, PV-10 and PH-10. It is developing PV-10 for treatment of several life threatening cancers, including metastatic melanoma, liver cancer and breast cancer.
Receive News & Ratings for Provectus Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Provectus Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.